Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes

被引：31
|
作者：
Hale, Clarence [1 ]
Wang, Minghan [1 ]
机构：
[1] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 07期
关键词：
11 beta-hydroxysteroid dehydrogenase; glucocorticoid receptor; cortisol; ex vivo activity; insulin resistance; Cushing's syndrome;
D O I：
10.2174/138955708784567421
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11 beta-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.
引用
收藏
页码：702 / 710
页数：9
相关论文
共 50 条
  • [1] 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease
    Anna Anderson
    Brian R. Walker
    Drugs, 2013, 73 : 1385 - 1393
  • [2] 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease
    Anderson, Anna
    Walker, Brian R.
    DRUGS, 2013, 73 (13) : 1385 - 1393
  • [3] 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
    Hughes, Katherine A.
    Webster, Scott P.
    Walker, Brian R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (04) : 481 - 496
  • [4] Inhibition of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) as a novel approach to type 2 diabetes treatment.
    Barf, T
    Vallgårda, J
    Kurz, G
    Alberts, P
    Abrahmsen, L
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U207 - U207
  • [5] The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors
    Cheng, Hengmiao
    Hoffman, Jacqui
    Le, Phuong
    Nair, Sajiv K.
    Cripps, Stephan
    Matthews, Jean
    Smith, Christopher
    Yang, Michele
    Kupchinsky, Stan
    Dress, Klaus
    Edwards, Martin
    Cole, Bridget
    Walters, Evan
    Loh, Christine
    Ermolieff, Jacques
    Fanjul, Andrea
    Bhat, Ganesh B.
    Herrera, Jocelyn
    Pauly, Tom
    Hosea, Natilie
    Paderes, Genevieve
    Rejto, Paul
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2897 - 2902
  • [6] Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
    Bauman, David R.
    Whitehead, Alan
    Contino, Lisa C.
    Cui, Jisong
    Garcia-Calvo, Margarita
    Gu, Xin
    Kevin, Nancy
    Ma, Xiuying
    Pai, Lee-yuh
    Shah, Kashmira
    Shen, Xiaolan
    Stribling, Sloan
    Zokian, Hratch J.
    Metzger, Joe
    Shevell, Diane E.
    Waddell, Sherman T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (12) : 3650 - 3653
  • [7] Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
    Jean, David J. St., Jr.
    Wang, Minghan
    Fotsch, Christopher
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (17) : 1508 - 1523
  • [8] Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
    Harno, Erika
    White, Anne
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2010, 21 (10): : 619 - 627
  • [9] Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)
    Scott, James S.
    Goldberg, Frederick W.
    Turnbull, Andrew V.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4466 - 4486
  • [10] The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors
    Yuan, Chester
    St. Jean, David J., Jr.
    Liu, Qingyian
    Cai, Lynn
    Li, Aiwen
    Han, Nianhe
    Moniz, George
    Askew, Ben
    Hungate, Randall W.
    Johansson, Lars
    Tedenborg, Lars
    Pyring, David
    Williams, Meredith
    Hale, Clarence
    Chen, Michelle
    Cupples, Rod
    Zhang, Jiandong
    Jordan, Steven
    Bartberger, Michael D.
    Sun, Yaxiong
    Emery, Maurice
    Wang, Minghan
    Fotsch, Christopher
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6056 - 6061
12345